Company: TELO
Filing Date: 2025-02-25
Form Type: 8-K
Source: 0001493152-25-008195
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple
Human Cell Lines

New
Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Supporting Cellular
Stability

Telomir
Pharmaceuticals, Inc. (NASDAQ:TELO) (“ Telomir”) today announced new preclinical findings demonstrating that Telomir-1 fully
reverses calcium dysregulation, a critical factor in cellular aging and disease progression, across multiple human cell lines.

The
study, conducted in human keratinocyte (HaCaT) and retinal (ARPE-19) cell lines, evaluated Telomir-1’s effects on intracellular
calcium influx, oxidative stress, and cell viability under conditions of oxidative challenge. The findings showed that Telomir-1 reduced
intracellular calcium overload, mitigated oxidative stress, and supported cellular integrity in response to extreme stress conditions.
Untreated cells exhibited signs of degeneration and death, while those treated with Telomir-1 demonstrated improved resilience.

Telomir-1
is believed to preserve cellular function, prevent the activation of cell death pathways, and stabilize key mechanisms that support longevity
and disease resistance. By addressing calcium dysregulation and oxidative stress - two key contributors to aging and disease - Telomir-1
has the potential to support cellular health and longevity.

Telomir
Pharmaceuticals is advancing preclinical studies to bring Telomir-1 into human trials as a potential first-in-class therapy for aging-related
conditions, including neurodegenerative disorders, retinal diseases, and metabolic dysfunction.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                      
  Dated:                 By:                       /s/                
                         Name:                     Erez               
                         Title:                    Chief